JP2009536629A - フェニルアミノ−ベンゾオキサゾール置換カルボン酸類、それらの製造方法、及び医薬品としての使用 - Google Patents

フェニルアミノ−ベンゾオキサゾール置換カルボン酸類、それらの製造方法、及び医薬品としての使用 Download PDF

Info

Publication number
JP2009536629A
JP2009536629A JP2009508193A JP2009508193A JP2009536629A JP 2009536629 A JP2009536629 A JP 2009536629A JP 2009508193 A JP2009508193 A JP 2009508193A JP 2009508193 A JP2009508193 A JP 2009508193A JP 2009536629 A JP2009536629 A JP 2009536629A
Authority
JP
Japan
Prior art keywords
alkyl
international publication
agonist
inhibitor
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009508193A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009536629A5 (cg-RX-API-DMAC7.html
Inventor
エリーザベト・デフォサ
マルクス・フォルマン
トーマス・クラブンデ
ヴィクトリア・ドゥロゾウ
ゲーアハルト・ヘスラー
ジークフリート・シュテンゲリン
グイド・ハシュケ
アンドレーアス・ヘルリング
シュテファン・バルトシェク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of JP2009536629A publication Critical patent/JP2009536629A/ja
Publication of JP2009536629A5 publication Critical patent/JP2009536629A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2009508193A 2006-05-11 2007-04-30 フェニルアミノ−ベンゾオキサゾール置換カルボン酸類、それらの製造方法、及び医薬品としての使用 Pending JP2009536629A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006021878A DE102006021878A1 (de) 2006-05-11 2006-05-11 Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PCT/EP2007/003806 WO2007131622A1 (de) 2006-05-11 2007-04-30 Phenylamino-benzoxazol substituierte carbonsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel

Publications (2)

Publication Number Publication Date
JP2009536629A true JP2009536629A (ja) 2009-10-15
JP2009536629A5 JP2009536629A5 (cg-RX-API-DMAC7.html) 2010-06-17

Family

ID=38371048

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009508193A Pending JP2009536629A (ja) 2006-05-11 2007-04-30 フェニルアミノ−ベンゾオキサゾール置換カルボン酸類、それらの製造方法、及び医薬品としての使用

Country Status (30)

Country Link
US (2) US20090149519A1 (cg-RX-API-DMAC7.html)
EP (1) EP2024347B1 (cg-RX-API-DMAC7.html)
JP (1) JP2009536629A (cg-RX-API-DMAC7.html)
KR (1) KR20090006846A (cg-RX-API-DMAC7.html)
CN (1) CN101437805B (cg-RX-API-DMAC7.html)
AR (1) AR060990A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007250213B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0711448A2 (cg-RX-API-DMAC7.html)
CA (1) CA2651660A1 (cg-RX-API-DMAC7.html)
CO (1) CO6241107A2 (cg-RX-API-DMAC7.html)
CY (1) CY1113177T1 (cg-RX-API-DMAC7.html)
DE (1) DE102006021878A1 (cg-RX-API-DMAC7.html)
DK (1) DK2024347T3 (cg-RX-API-DMAC7.html)
ES (1) ES2391203T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20120829T1 (cg-RX-API-DMAC7.html)
IL (1) IL195179A0 (cg-RX-API-DMAC7.html)
MA (1) MA30402B1 (cg-RX-API-DMAC7.html)
MX (1) MX2008014102A (cg-RX-API-DMAC7.html)
MY (1) MY148258A (cg-RX-API-DMAC7.html)
NO (1) NO20085068L (cg-RX-API-DMAC7.html)
NZ (1) NZ572692A (cg-RX-API-DMAC7.html)
PL (1) PL2024347T3 (cg-RX-API-DMAC7.html)
PT (1) PT2024347E (cg-RX-API-DMAC7.html)
RS (1) RS52450B (cg-RX-API-DMAC7.html)
RU (1) RU2434003C2 (cg-RX-API-DMAC7.html)
SI (1) SI2024347T1 (cg-RX-API-DMAC7.html)
TW (1) TW200812987A (cg-RX-API-DMAC7.html)
UY (1) UY30338A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007131622A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200808490B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013039140A1 (ja) * 2011-09-14 2013-03-21 第一三共株式会社 縮合へテロ環誘導体

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
CA2662242C (en) 2006-09-07 2012-06-12 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
EP2064193A1 (en) 2006-09-07 2009-06-03 Amgen, Inc Heterocyclic gpr40 modulators
ES2446419T3 (es) 2007-04-16 2014-03-07 Amgen, Inc Moduladores de GPR40 de ácidos bifenilfenoxi, tiofenil y aminofenilpropanoico sustituidos
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP5591706B2 (ja) 2007-10-10 2014-09-17 アムジエン・インコーポレーテツド 置換ビフェニルｇｐｒ４０調節因子
US8716283B2 (en) 2007-11-07 2014-05-06 University Of Massachusetts Type III secretion inhibitors, analogs and uses thereof
JP2011515341A (ja) 2008-03-06 2011-05-19 アムジエン・インコーポレーテツド 代謝障害の治療に有用な立体配座的に制限されたカルボン酸誘導体
EP2358656B1 (en) 2008-10-15 2014-01-01 Amgen, Inc Spirocyclic gpr40 modulators
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
WO2011140190A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Tetrazolones as inhibitors of fatty acid synthase
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
BR112013004882A2 (pt) 2010-08-31 2016-05-03 Snu R&Db Foundation utilização de reprogramação fetal de agonista ppar delta
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
WO2015084692A1 (en) 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2015119899A1 (en) 2014-02-06 2015-08-13 Merck Sharp & Dohme Corp. Antidiabetic compounds
EP3273981B1 (en) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of diabetes
CN118084940A (zh) 2018-02-13 2024-05-28 吉利德科学公司 Pd-1/pd-l1抑制剂
AU2019255750B2 (en) 2018-04-19 2021-10-21 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
CN112955435B (zh) 2018-10-24 2024-09-06 吉利德科学公司 Pd-1/pd-l1抑制剂
US11976052B2 (en) 2019-01-11 2024-05-07 Naegis Pharmaceuticals Inc. Leukotriene synthesis inhibitors

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5070362A (cg-RX-API-DMAC7.html) * 1973-10-23 1975-06-11
JPH07149636A (ja) * 1990-06-14 1995-06-13 Pfizer Inc 血糖低下剤としての３−アリール−２−ヒドロキシプロピオン酸誘導体および同族体
WO2002053534A1 (en) * 2000-12-28 2002-07-11 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
JP2002521375A (ja) * 1998-07-23 2002-07-16 アストラゼネカ アクチエボラーク 化合物
JP2002537292A (ja) * 1999-02-16 2002-11-05 アベンティス・フアーマ・リミテッド 二環化合物およびそれらのインテグリン受容体リガンドとしての使用
JP2003520799A (ja) * 2000-01-21 2003-07-08 アストラゼネカ アクチエボラーク インテグリンα４β１受容体及びＶＣＡＭ−１及び／又はフィブロネクチンの間の相互作用のインヒビターとしての二環式ヘテロアリール化合物
JP2004521868A (ja) * 2000-11-04 2004-07-22 アベンティス・フアーマ・リミテッド 置換アルカン酸
WO2005070906A1 (en) * 2004-01-21 2005-08-04 Novartis Ag Organic compounds
JP2005343792A (ja) * 2003-05-30 2005-12-15 Takeda Chem Ind Ltd 縮合環化合物
JP2006056830A (ja) * 2004-08-20 2006-03-02 Dai Ichi Seiyaku Co Ltd ２−アリールアミノベンゾオキサゾール誘導体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4025637A (en) * 1973-10-23 1977-05-24 Lilly Industries, Ltd. 2,5 OR 2,6 Disubstituted benzoxazoles
US5296486A (en) * 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
DE69327536T2 (de) * 1992-10-14 2000-07-06 Merck & Co., Inc. Fibrinogenrezeptor-antagonisten
PT966465E (pt) * 1997-03-14 2003-11-28 Vertex Pharma Inibidores do enzima imfdh
US7470712B2 (en) * 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5070362A (cg-RX-API-DMAC7.html) * 1973-10-23 1975-06-11
JPH07149636A (ja) * 1990-06-14 1995-06-13 Pfizer Inc 血糖低下剤としての３−アリール−２−ヒドロキシプロピオン酸誘導体および同族体
JP2002521375A (ja) * 1998-07-23 2002-07-16 アストラゼネカ アクチエボラーク 化合物
JP2002537292A (ja) * 1999-02-16 2002-11-05 アベンティス・フアーマ・リミテッド 二環化合物およびそれらのインテグリン受容体リガンドとしての使用
JP2003520799A (ja) * 2000-01-21 2003-07-08 アストラゼネカ アクチエボラーク インテグリンα４β１受容体及びＶＣＡＭ−１及び／又はフィブロネクチンの間の相互作用のインヒビターとしての二環式ヘテロアリール化合物
JP2004521868A (ja) * 2000-11-04 2004-07-22 アベンティス・フアーマ・リミテッド 置換アルカン酸
WO2002053534A1 (en) * 2000-12-28 2002-07-11 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
JP2005343792A (ja) * 2003-05-30 2005-12-15 Takeda Chem Ind Ltd 縮合環化合物
WO2005070906A1 (en) * 2004-01-21 2005-08-04 Novartis Ag Organic compounds
JP2006056830A (ja) * 2004-08-20 2006-03-02 Dai Ichi Seiyaku Co Ltd ２−アリールアミノベンゾオキサゾール誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6012050741; 長瀬 博: 最新 創薬化学 上巻 第１版, 19980815, ｐ．２３６-２４０, 株式会社テクノミック *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013039140A1 (ja) * 2011-09-14 2013-03-21 第一三共株式会社 縮合へテロ環誘導体

Also Published As

Publication number Publication date
WO2007131622A1 (de) 2007-11-22
RU2434003C2 (ru) 2011-11-20
MX2008014102A (es) 2008-11-14
US20090149519A1 (en) 2009-06-11
CO6241107A2 (es) 2011-01-20
HK1131978A1 (en) 2010-02-12
NO20085068L (no) 2009-02-04
PT2024347E (pt) 2012-10-09
EP2024347B1 (de) 2012-08-01
AR060990A1 (es) 2008-07-30
BRPI0711448A2 (pt) 2011-11-08
KR20090006846A (ko) 2009-01-15
IL195179A0 (en) 2009-08-03
AU2007250213A1 (en) 2007-11-22
MY148258A (en) 2013-03-29
ZA200808490B (en) 2009-10-28
CY1113177T1 (el) 2016-04-13
CN101437805A (zh) 2009-05-20
CA2651660A1 (en) 2007-11-22
EP2024347A1 (de) 2009-02-18
AU2007250213B2 (en) 2013-04-11
DE102006021878A1 (de) 2007-11-15
PL2024347T3 (pl) 2013-01-31
UY30338A1 (es) 2008-01-02
NZ572692A (en) 2011-03-31
US20130303578A1 (en) 2013-11-14
CN101437805B (zh) 2012-05-30
SI2024347T1 (sl) 2012-11-30
RS52450B (sr) 2013-02-28
HRP20120829T1 (hr) 2012-11-30
RU2008148838A (ru) 2010-06-20
ES2391203T3 (es) 2012-11-22
DK2024347T3 (da) 2012-10-29
TW200812987A (en) 2008-03-16
MA30402B1 (fr) 2009-05-04
US8748465B2 (en) 2014-06-10

Similar Documents

Publication Publication Date Title
JP5277159B2 (ja) ４，５−ジフェニル−ピリミジニルアミノ置換カルボン酸類、それらの製造方法及び医薬品としての使用
EP2024339B1 (de) 4,5-diphenyl-pyrimidinyl-oxy oder -mercapto substituierte carbonsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JP2009536629A (ja) フェニルアミノ−ベンゾオキサゾール置換カルボン酸類、それらの製造方法、及び医薬品としての使用
EP2024338B1 (de) 4,5-diphenyl-pyrimidinyl substituierte carbonsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JP5427784B2 (ja) （カルボキシルアルキレン−フェニル）−フェニル−オキサルアミド、その製造方法、及び薬剤としてのその使用
JP2011509239A (ja) （シクロプロピルフェニル）フェニルオキサルアミド、その製造方法、及び薬剤としてのその使用
JP2010524987A (ja) ２−ヘテロアリール−ピロロ［３，４−ｃ］ピロール誘導体及びｓｃｄ阻害剤としてのそれらの使用
JP2009516714A (ja) 高脂血症を治療するためのヒドロキシ置換ジフェニルアゼチジノン
JP2010536811A (ja) アゾロアリン誘導体、その製造方法、こうした化合物を含む医薬、およびその使用
HK1130800B (en) 4,5-diphenyl-pyrimidinyl-amino substituted carboxylic acids, method for the production and use thereof as medicaments
HK1130801A (en) 4,5-diphenyl-pyrimidinyl-oxy or -mercapto substituted carboxylic acids, method for the production and use thereof as medicaments
HK1131978B (en) Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100423

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121228

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130618

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131217